Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Outlook Therapeutics's price to book ratio was 42.3× on Jul 31, 2023, against 5.2× a year earlier. Over the last 3 years it ranged from 4.7× to 58.5×, with a median of 27.1×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jul 31, 2023 | 42.3× | +14.2 |
| 2022 | Dec 30, 2022 | 28.1× | −24.0 |
| 2021 | Dec 31, 2021 | 52.1× | −6.4 |
| 2020 | Dec 31, 2020 | 58.5× | – |
See a number that looks wrong?